<< Back to News

NCCN and ASCO guidelines regarding the use of granulocyte colony-stimulating factor (G-CSF), inclusive of pegfilgrastim.


Due to the COVID-19 pandemic, the updated NCCN and ASCO guidelines have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20% or higher risk of febrile neutropenia to now include those regimens with a risk of 10-20%, which includes all of the intermediate risk chemotherapy regimens.


This important information will be beneficial to share with your members during this Public Health Emergency. If you have any questions on these guidelines, I’d be happy to connect you with a member of our Medical Affairs team (800-483-3692). 


For your convenience, we have provided the following:


·         Internet link to both NCCN and ASCO guidelines for your reference and review.

§  NCCN Covid-19 Link: https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf

§  ASCO Covid-19 Link: https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19